Biofilm-Related Genes: Analyses in Multi-Antibiotic Resistant *Acinetobacter Baumannii* Isolates From Mainland China

**Background:** *Acinetobacter baumannii* is an important nosocomial pathogen which shows a high level of mortality risk. Several papers have reported biofilm formation as a well-known pathogenic mechanism in *A. baumannii* infections and exceptional antibiotic resistance. The study aims to explore the potential relationships between biofilm-related genes and antimicrobial resistance.

**Material/Methods:** Samples from 122 patients with lower respiratory tract infections of *A. baumannii* were collected at Fujian Longyan First Hospital from January 2013 to September 2014. *A. baumannii* was isolated from sputum specimens. Biofilm-related genes including *abaI*, *csuE*, *ompA*, and *bla-PER1* were analyzed by PCR. The minimum inhibitory concentration method was used to determine the sensitivity of each strain to antibiotics.

**Results:** The clinical manifestations of *A. baumannii*-induced lower respiratory tract infections lacked specificity. Infected patients were most commonly admitted to intensive care units (54.9%) and frequently had chronic obstructive pulmonary disease (27.0%). The detection rates of *abaI* and *csuE* were both 59.8%, and those of *ompA* and *bla-PER1* were 100% and 0%, respectively. After genetic testing, antimicrobial resistance to amikacin, ampicillin/sulbactam, and 14 other types of antimicrobials was higher in *abaI*- and *csuE*-positive strains than in *abaI* - and *csuE*-negative strains (P<0.05).

**Conclusions:** The findings of our study suggest that *abaI* - and *csuE*-positive *Acinetobacter baumannii* strains are associated with a higher incidence of antibiotic resistance in 14 types of antimicrobials.

**MeSH Keywords:** **Bacterial Infections** • **Drug Resistance, Multiple, Bacterial** • **Genes, Bacterial**

**Full-text PDF:** http://www.medscimonit.com/abstract/index/idArt/898959
Background

*Acinetobacter baumannii* is an important nosocomial pathogen that causes pneumonia, bacteremia, meningitis, urinary tract infections, and other inflammation-related diseases [1–5]. It is difficult to treat *A. baumannii* infections owing to the occurrence of drug resistance and the ability of the pathogen to propagate worldwide. This infection contributes to the high mortality rates of in-patients (23%) and patients in the intensive care unit (ICU; 43%) and represents a major clinical issue [6].

Currently, *A. baumannii* drug resistance is believed to be related to specific antibiotic hydrolyses produced by *A. baumannii*; these hydrolyses could alter drug-binding proteins, bacterial structure, and the number of porins, and could increase the activity of efflux pumps [7–10]. Furthermore, *A. baumannii* can live in the form of a biofilm in the external environment, resistant to disinfectants, ultraviolet light, and host immune defenses. This biofilm increases the difficulty of preventing and controlling *A. baumannii* infections [11].

A previous review illustrated several specific genes, including *csuA/BABCDE, ompA, abal*, and *pgaABCDE*, that may determine the biofilm formation of *A. baumannii* [12]. Furthermore, alternative protein complexes involved in biofilm formation are assembled in different *A. baumannii* strains and are highly correlated with the uneven distributions of different biofilm-associated protein (BAP) types [13]. The relationship between biofilm-related genes and *A. baumannii* biofilm formation was described in previous studies [14–18]. For example, Breij et al. suggested that there may be an association between the *csuA/BABCDE* gene and *A. baumannii* biofilm formation on abiotic surfaces [14]. Furthermore, *ompA* can be integrated into host epithelial cell and mitochondrial membranes and induce cell death, or participate in the extrusion of compounds from the periplasmic space through the outer membrane and couple with inner membrane efflux systems, which may be associated with drug resistance in *A. baumannii* infections [16]. The autoinducer synthase *abal* is necessary for biofilm formation and plays an important role in the late stages of biofilm maturation [15,17]. Moreover, the ability of *A. baumannii* to adhere to epithelial cells may be enhanced by *bla-PER1* [18]. Currently, although several potential relationships have been detected in previous studies, the relationship between biofilm-related genes, biofilm formation, and drug resistance of *A. baumannii* in China remains unclear. Furthermore, the correlations between antibiotic resistance and the four *A. baumannii* genes related to biofilm formation are still controversial. Therefore, we conducted a retrospective study to explore the potential association between the four biofilm-related genes and drug resistance by detecting *csuA/BABCDE, ompA, abal*, and *bla-PER1* in *A. baumannii* isolates from clinical specimens.

Material and Methods

**Ethics statement**

This study was approved by the Ethics Committee of Longyan First Affiliated Hospital of Fujian Medical University, Longyan, Fujian, China (2012001). The purpose and procedures of the study were carefully explained to all participants and written informed consent was obtained from all participants. All the clinical isolates analyzed in this work were collected as part of routine medical care. All the data analyzed in this work had already been anonymized before analysis.

**Patients and inclusion criteria**

One hundred twenty-two patients with lower respiratory tract infection by *A. baumannii* were enrolled in this study after hospitalization in various departments at Fujian Longyan First Hospital between January 2013 and September 2014. The exclusion criteria included immune deficiency and previous use of hormone therapy. Patients’ primary disease, aggressive treatment, clinical symptoms, temperature, white blood cell count (WBC), and X-ray examination results were recorded by investigators. The patients had clinical symptoms that included cough with purulent sputum or increasing sputum volume, moist crackles, or lung X-ray examination with pulmonary infiltrates or with fuzzy and increased lung markings. Furthermore, we also carried out laboratory tests, imaging examinations, and microbiological examinations. Using “Diagnostic Criteria for Hospital Infections” as the basis for diagnosis, patients were eligible for inclusion in the study if the following criteria were met: (1) *A. baumannii* was detected from two consecutive sputum cultures, and (2) *A. baumannii* ≥10^5 CFU/mL was detected from lower respiratory tract secretions that were collected by fiber optic bronchoscopy or artificial airways.

**Source of bacterial strains**

*A. baumannii* bacteria were obtained from sputum specimens from the first deep lung expectorant of patients after waking and rinsing their mouths using normal saline. Strains were detected using a BD Phoenix100 automated microbial identification system (Becton Dickinson and Company, NJ, USA). The reference strains *Escherichia coli* ATCC25922 and *Pseudomonas aeruginosa* ATCC27853 were used as controls (OXOID Company, Basingstoke, England).

**Genomic DNA extraction**

A pure culture colony was picked and placed in a 1.0 mL centrifuge tube. *A. baumannii* genomic DNA was extracted using a TIANGEN bacterial genomic DNA extraction kit (TIANGEN...
Biotech Company, Beijing, China) according to the manufacturer’s instructions. DNA was stored at –20°C until use.

**Gene detection**

Target genes were detected using polymerase chain reaction (PCR). The various target gene primer sequences [16–18] and product lengths are shown in Table 1. Each biofilm-associated gene amplification reaction included 1 µL each of P1 and P2 primers (10 nM), 3 µL of 200 mM dNTPs, 3 µL of buffer containing 15 mM MgCl₂, 2 µL DNA template, 5 U/µL Taq enzyme (1 µL), and 19 µL of double-distilled H₂O for a total reaction volume of 30 µL.

The PCR thermal cycling parameters for *abaI* and *csuE* were an initial denaturation at 95°C for 10 minutes; followed by 35 cycles of 95°C for 30 seconds, 63°C for 30 seconds, and 72°C for 1 minute; and a final extension at 72°C for 10 minutes. The PCR thermal cycling parameters for *ompA* and *bla-PER1* were an initial denaturation at 95°C for 10 minutes; followed by 35 cycles of 95°C for 30 seconds, 52°C for 30 seconds, and 72°C for 1 minute; and a final extension at 72°C for 10 minutes.

By comparing the resulting bands and a DNA base pair marker following 2% agarose gel electrophoresis, products that showed the expected molecular weight were regarded as positive [19].

**Drug sensitivity test**

The microdilution quantitative minimum inhibitory concentration (MIC) method was used to determine the antimicrobial susceptibility of each strain. According to the US CLSI2013 susceptibility criteria, susceptibility paper from the OXOID Company was applied for the assessment of drug sensitivity. Multidrug resistance was defined as isolates showing drug resistance to all classes excluding polymyxin.

**Statistical analyses**

Baseline data are presented as the mean ± standard deviation and rate. Comparisons between positive and negative genes were made using t-tests and χ² tests. First, we used univariate logistic regression to determine any potential confounders. Furthermore, drug resistance was investigated by logistic regression for analyzing the odds ratio after adjustment for gender, mean age, department, ventilator, tracheotomy, cardiovascular disease, and diabetes. Statistical analyses were performed with two-sided tests. Differences with *P*-values of less than 0.05 were considered statistically significant. The data were analyzed using Statistical Package for the Social Sciences version 19.0 (SPSS 19.0).

**Results**

**Baseline characteristics**

As shown in Table 2, there were 102 men and 20 women enrolled in this study. The mean age of the enrolled patients was 64±22 years. Additionally, 54.9% (67/122) of *A. baumannii*-infected patients were admitted to the ICU, and 33 patients (27%, 33/122) had chronic obstructive pulmonary disease (COPD). The long-term invasive treatments to which patients were exposed included tracheotomy, mechanical ventilation, intravenous indwelling catheterization, retention catheterization, and sputum suction. The proportion of infections associated with tracheotomy, mechanical ventilation, and sputum suction were 74.07% (40/54), 71.67% (43/60), and 46.67% (28/60), respectively. Patients had cough, sputum, pulmonary moist rales, imaging changes, and other clinical symptoms.

| Gene   | Primer sequence (5’-3’) | Product length |
|--------|-------------------------|----------------|
| *abaI* | P1 GTACAGTCGACGTATTTGTTGAATATTTGGG | 382 bp         |
|        | P2 CGTACGTCTAGAGTAATGAGTTGTTTTGCGCC |               |
| *csuE* | P1 AATCGATTTCTGAGCTGAAGTCGACGTTTTGAC | 976 bp         |
|        | P2 CGACTTGTACCGTGACCGTATCTTGAAG   |               |
| *ompA* | P1 CAATTGTATCTTGAGAG             | 966 bp         |
|        | P2 GCCCTGTAGAACAAGCA             |               |
| *bla-PER1* | P1 ATGATGTGATTAAAAAGC  | 978 bp         |
|        | P2 CCATCGCTTGGAGGCGCA           |               |

Pan-drug resistance was defined as isolates showing drug resistance to three or more of the following five classes of antibiotics: cephalosporins, carbapenems, compounds of β-lactamase inhibitors, fluoroquinolones, and aminoglycosides.

Table 1. Target gene PCR primer sequences and product lengths.
In the 122 sputum specimens, the detection rates of \textit{abaI} and \textit{csuE} were both 59.8%, and those of \textit{ompA} and \textit{bla-PER1} were 100% and 0%, respectively. The results of our analysis of biofilm-related genes are shown in Table 3.

### Table 2. Baseline characteristics of patients with \textit{A. baumannii} infections.

|                        | Mean/number | Range/rate |
|------------------------|-------------|------------|
| Gender (male)          | 102         | 83.6       |
| Mean age               | 64          | (1, 98)    |
| Length of hospital stay (day) | 16.5     | (4, 95)    |
| Body temperature (admission) | 37.15      | (35.0, 39.6) |
| Body temperature (return samples) | 37.70  | (36.0, 39.1) |
| Body temperature (1 day after infection) | 37.40 | (35.5, 40.2) |
| Body temperature (7 days after treatment) | 37.10 | (36.0, 39.1) |
| WBC (admission)        | 11.2        | (2.86, 32.14) |
| WBC (return samples)   | 12.46       | (2.77, 29.81) |
| WBC (1 day after infection) | 12.21   | (2.35, 30.81) |
| WBC (7 days after treatment) | 11.25  | (4.94, 26.05) |
| Intensive Care Unit    | 67          |            |
| Respiratory Department | 19          | 15.6       |
| COPD                   | 33          | 27.0%      |
| Cardiovascular disease | 25          | 20.5%      |
| Cerebral trauma        | 14          | 11.5%      |
| Diabetes               | 19          | 15.6%      |
| Hypertension           | 26          | 21.3%      |
| Ventilator             | 43/60       | 71.67%     |
| Tracheotomy            | 40/54       | 74.07%     |
| Urine tube             | 14/42       | 33.33%     |
| Venous catheterization | 7/29        | 24.14%     |
| Sputum suction         | 28/60       | 46.67%     |
| Fever                  | 57          | 46.72%     |
| Small shape shadow     | 70          | 57.38      |
| Large shape shadow     | 40          | 32.79      |

### Table 3. Biofilm-related gene expression.

| Gene    | Positive | Positive rate (%) |
|---------|----------|-------------------|
| \textit{abaI} | 73       | 59.8              |
| \textit{csuE} | 72       | 59.8              |
| \textit{ompA} | 122      | 100.0             |
| \textit{bla-PER1} | 0        | 0.0               |

### Biofilm-related gene analysis

In the 122 sputum specimens, the detection rates of \textit{abaI} and \textit{csuE} were both 59.8%, and those of \textit{ompA} and \textit{bla-PER1} were 100% and 0%, respectively. The results of our analysis of biofilm-related genes are shown in Table 3.

### Antibiotic resistance

Resistance rates are shown in Table 4. \textit{abaI}- and \textit{csuE}-positive and negative specimens showed statistically significant differences in the rates of resistance to amikacin, ampicillin/sulbactam, cefepime, cefoperazone/sulbactam, cefotaxime, ceftazidime, ciprofloxacin, gentamicin, imipenem, meropenem,
Table 4. Differences in abaI and csuE positivity and responses to antimicrobial agents.

| Drug                     | DRR (n%) | abaI DRR (n%) | P   | csuE DRR (n%) | P   |
|--------------------------|----------|---------------|-----|---------------|-----|
| Amikacin                 | 53.3     | 80.82         | <0.01 | 78.08         | 16.33 | <0.001 |
| Ampicillin/Sublactam     | 65.6     | 97.26         | 18.37 | 94.52         | 22.45 | <0.001 |
| Cefepime                 | 65.6     | 98.63         | 16.32 | 93.15         | 24.49 | <0.001 |
| Cefoperazone/Sublactam   | 28.7     | 45.20         | 4.08  | 40.09         | 10.20 | <0.001 |
| Cefotaxime               | 63.9     | 97.26         | 14.29 | 93.15         | 10.20 | <0.001 |
| Ceftazidime              | 63.9     | 97.26         | 14.29 | 93.15         | 10.20 | <0.001 |
| Ciprofloxacin            | 67.2     | 97.26         | 22.45 | 94.52         | 26.53 | <0.001 |
| polymyxin E              | 0.0      | 0.00          | 0.00  | 0.00          | 0.00  | >0.05* |
| Gentamicin               | 64.8     | 97.26         | 16.33 | 93.15         | 22.45 | <0.001 |
| Imipenem                 | 60.7     | 95.89         | 8.16  | 91.78         | 14.28 | <0.001 |
| Meropenem                | 59.8     | 94.52         | 8.16  | 91.78         | 12.24 | <0.001 |
| Piperacillin/Tazobactam  | 61.5     | 95.89         | 18.18 | 91.78         | 16.33 | <0.001 |
| Tetracycline             | 70.5     | 95.89         | 32.65 | 94.52         | 34.69 | <0.001 |
| SMZco                    | 65.6     | 94.52         | 22.45 | 91.78         | 26.53 | <0.001 |
| Levofloxacin             | 63.1     | 95.89         | 14.26 | 93.15         | 18.37 | <0.001 |

DRR – drug resistance rate.

Table 5. Associations between specific drug resistance rates and abaI and csuE positivity after adjustment for various factors.

| Drug                     | Adjusted odds ratio for abaI | 95% CI for abaI | P value for abaI | Adjusted odds ratio for csuE | 95% CI for csuE | P value for csuE |
|--------------------------|-------------------------------|-----------------|-----------------|-------------------------------|-----------------|-----------------|
| Amikacin                 | 41.57                         | 14.03–123.17    | <0.001          | 15.84                         | 5.82–43.15      | <0.001          |
| Ampicillin               | 741.65                        | 38.33–14349.88  | <0.001          | 89.71                         | 17.81–451.83    | <0.001          |
| Cefepime                 | 3466.57                       | 44.60–269445.75 | <0.001          | 132.66                        | 15.57–1130.04   | <0.001          |
| Sulbactam                | 102.99                        | 11.81–1898.31   | <0.001          | 316.75                        | 30.33–3308.09   | <0.001          |
| Ceftazidime              | 167.96                        | 14.72–1916.05   | <0.001          | 76.66                         | 10.07–583.30    | <0.001          |
| Ciprofloxacin            | 181.58                        | 31.77–1037.97   | <0.001          | 142.71                        | 21.51–946.93    | <0.001          |
| Gentamicin               | 224.19                        | 33.47–1501.67   | <0.001          | 193.38                        | 20.88–1791.48   | <0.001          |
| Imipenem                 | 272.09                        | 46.87–1579.63   | <0.001          | 316.75                        | 30.33–3308.09   | <0.001          |
| Meropenem                | 269.92                        | 46.49–1567.26   | <0.001          | 284.59                        | 29.22–2772.08   | <0.001          |
| Piperacillin              | 511.61                        | 49.60–5276.73   | <0.001          | 191.58                        | 22.62–1622.41   | <0.001          |
| Tetracycline             | 31.35                         | 8.15–120.54     | <0.001          | 32.87                         | 8.57–126.02     | <0.001          |
| SMZco                    | 60.51                         | 15.34–238.79    | <0.001          | 35.65                         | 10.07–126.24    | <0.001          |
| Levofloxacin             | 267.31                        | 34.07–2097.17   | <0.001          | 138.57                        | 22.46–855.06    | <0.001          |

CI – confidence interval. Adjusted: gender, mean age, department, ventilator, tracheotomy, cardiovascular disease, and diabetes.
piperacillin/tazobactam, tetracycline, cotrimoxazole (SMZco), and levofloxacin (P<0.001). Moreover, there was a statistically significant difference between abal-positive and abal-negative groups (P<0.05) whereas no statistically significant difference was observed between csuE-positive and csuE-negative groups (P>0.05). The odds ratios for the association between specific drug resistance rates and positivity for the abal and csuE genes are presented in Table 5. Overall, we noted that abal and csuE positivity were associated with a statistically significant impact on amikacin, ampicillin, cefepime, sulbactam, cefotaxime, ceftazidime, ciprofloxacin, gentamicin, imipenem, meropenem, piperacillin, tetracycline, SMZco, and levofloxacin resistance after adjustment for gender, mean age, department, ventilator, tracheotomy, cardiovascular disease, and diabetes.

Discussion

A. baumannii is an opportunistic pathogen that can colonize the skin, conjunctiva, oral cavities, respiratory tract, gastrointestinal tract, and urinary tract [20]. Furthermore, A. baumannii infections frequently occur in the intensive care unit and respiratory department. These patients are often in critical condition, have lower immune function, exhibit poor nutritional status, and may also have diabetes, cancer, chronic wasting disease, and other diseases of the brain, heart, kidneys, or lungs. Thus, these patients often have decreased resistance and increased susceptibility to infection [21]. The symptoms caused by lower respiratory tract infections of A. baumannii include cough, sputum, and pulmonary moist rales. In addition, patients often exhibit distinct x-ray images, such as multiple scattered small patchy shadows, large patchy shadows, cystic lung or cylindrical bronchiectasis, and pleural effusions, which lack clinical specificity. Therefore, microbiological examinations are needed to confirm A. baumannii infection as soon as possible in order to maximize recovery rates. The findings of our study suggested that abal-positive and csuE-positive strains were associated with 14 types of antimicrobial resistance, as shown in Table 4. Furthermore, after adjusting for gender, mean age, department, ventilator, tracheotomy, cardiovascular disease, and diabetes, abal and csuE were associated with significant effects on amikacin, ampicillin, cefepime, sulbactam, cefotaxime, ceftazidime, ciprofloxacin, gentamicin, imipenem, meropenem, piperacillin, tetracycline, SMZco, and levofloxacin resistance.

Bacterial biofilms are associated with problems in the prevention and treatment of A. baumannii infection [11]. Biofilms irreversibly adhere in the host’s tissues or on abiotic surfaces and are supported by polymer matrices that are secreted by the microorganisms themselves, facilitating the formation of bacterial communities [22]. This viscous matrix can separate bacteria from harmful external factors, thereby increasing the resistance of the microbial community [22]. These observations may be explained as follows: (1) permeation limitation: bacteria at high density in biofilms can produce an extracellular matrix that impedes antibiotic penetration; (2) nutrition restrictions: bacteria in biofilms are maintained in a state of low metabolism and a slow growth rate, making them less sensitive to outside stimuli, such as antibiotics; (3) phenotype inference: biological membranes select or induce strains with resistant phenotypes and increase the number of antibiotic resistance genes and the expression of resistance efflux pumps, leading to drug resistance; (4) immune suppression: A. baumannii biofilms are a natural physical barrier that limit immune-mediated killing of the organism; and (5) quorum sensing: following an increase in the number of A. baumannii, some bacteria are detached from the surface of the biofilm by quorum sensing and are transformed into a planktonic growth state, allowing bacteria to adhere to appropriate media and leading to the spread of infection and relapse [14,23,24].

The clinical signs of A. baumannii-infected patients and the possible factors that influence drug resistance were also examined in this study. The reasons for this include permeation limitation, nutrition restrictions, phenotype inference, immune suppression, and quorum sensing, as discussed above. Therefore, the following prevention and treatment methods are recommended: (1) regular disinfection of wards and medical contain- ers should be conducted; (2) medical personnel should prac- tice hand hygiene; (3) the duration of mechanical ventilation and body catheterization should be shortened; and (4) early diagnosis and drug resistance testing should be a priority in order to enhance preventive measures.

Our study had several limitations. First, stratified analyses based on potential confounders were not conducted due to the insufficient sample size. Second, patients with different disease statuses and admitted to different clinical centers were enrolled in this study, which may have affected the observed results.

Thus, an improved understanding of the association between biofilm formation and resistance mechanisms is needed because once drug-resistant strains form biofilms, treatment becomes extremely difficult. Abal- and csuE-positive strains were the most resistant to the 14 types of antimicrobials; therefore, detecting these genes can guide antibiotic use in A. bauman- nii-infected patients. Further studies are needed to determine whether strains carrying abal and csuE are associated with biofilm formation.

Conclusions

A. baumannii infected patients were most commonly admitted to intensive care units and the respiratory department, and the patients frequently had chronic obstructive pulmonary disease.
The patients infected with *A. baumannii*-induced lower respiratory tract infections lacked clinical specificity. The majority of the *A. baumannii* isolates from mainland China were susceptible to polymyxin E. *Abal* and *csuE*-positive strains were associated with higher incidence of 14 types of antimicrobial resistance. Detecting the *abai* and *csuE* genes can provide important information for clinical treatment by certain antibiotics. An improved understanding of the association between biofilm formation and resistance mechanisms is needed, and some preventive measures such as shortening the duration of mechanical ventilation should be instituted to avoid biofilm formation.

**Conflict of interest statement**

The authors declare that they have no conflict of interest.

**References:**

1. Teng SQ, Yen MY, Ou TY et al: Comparison of pneumonia- and non-pneumonia-related *Acinetobacter baumannii* bacteremia: Impact on empiric therapy and antibiotic resistance. J Microbiol Immunol Infect, 2015; 48: 525–30

2. Cakirlar FK, Ciftci IH, Gonullu N: OXA-type carbapenemases and susceptibility of colistin and tigecycline among carbapenem-resistant *Acinetobacter baumannii* isolates from patients with bacteremia in Turkey. Clin Lab, 2015; 61: 741–47

3. Moon C, Kwak YG, Kim BN et al: Implications of postneurosurgical meningitis caused by carbapenem-resistant *Acinetobacter baumannii*. J Infect Chemother, 2013; 19: 916–19

4. Mizrahi A, Lambert T, Vidal B et al: Pseudo-outbreak of Oxa-23-mediated carbapenem-resistant *Acinetobacter baumannii* in urinary tract infections caused by an automated urine analyzer. Infect Control Hosp Epidemiol, 2014; 35: 1440–41

5. Lin L, Tan B, Pantapalangkoor P et al: Inhibition of LpxC protects mice from resistant *Acinetobacter baumannii* by modulating inflammation and enhancing phagocytosis. MBio, 2012; 3(5): pii: e00312-12

6. Peleg AV, Seifert H, Paterson DL: *Acinetobacter baumannii*: Emergence of a successful pathogen. Clin Microbiol Rev, 2008, 21: 538–82

7. Nowak P, Paluchowska PM, Budak A: Co-occurrence of carbapenem and aminoglycoside resistance genes among multidrug-resistant clinical isolates of *Acinetobacter baumannii* from Cracow, Poland. Med Sci Monit Basic Res, 2014; 20: 9–14

8. Szejbach A, Mikucka A, Bogiel T et al: Usefulness of phenotypic and genotypic methods for metallo-beta-lactamases detection in carbapenem-resistant *Acinetobacter baumannii* strains. Med Sci Monit Basic Res, 2013; 19: 32–36

9. Elsa Salazar de Vegas, Nieves B, Ruiz M et al: Molecular epidemiology and characterization of resistance mechanisms to various antimicrobial agents in *Acinetobacter baumannii* isolated in Mérida, Venezuela. Med Sci Monit, 2007; 13(4): BR89–94

10. Bonomo RA, Szabo D: Mechanisms of multidrug resistance in *Acinetobacter* species and *Pseudomonas aeruginosa*. Clin Infect Dis, 2006; 43(Suppl.2): S49–56

11. Cos P, Tote K, Horemans T, Maes L: Biofilms: An extra hurdle for effective antimicrobial therapy. Curr Pharm Des, 2010; 16: 2279–95

12. Longo F, Vuotto C, Donelli G: Biofilm formation in *Acinetobacter baumannii*. New Microbiol, 2014; 37: 119–27

13. De Gregorio E, Del Franco M, Martinucci M et al: Biofilm-associated proteins. News from *Acinetobacter*. BMC Genomics, 2015; 16: 933

14. de Breij A, Gaddy I, van der Meer I et al: CsuA/BABCDE-dependent pili are not involved in the adherence of *Acinetobacter baumannii* ATCC19606(T) to human airway epithelial cells and their inflammatory response. Res Microbiol, 2009; 160: 213–18

15. Loefhelm TW, Luke NR, Campagnari AA: Identification and characterization of an *Acinetobacter baumannii* biofilm-associated protein. J Bacteriol, 2008; 190: 1036–44

16. Smani Y, Fabrega A, Roca I et al: Role of OmpA in the multidrug resistance phenotype of *Acinetobacter baumannii*. Antimicrob Agents Chemother, 2014; 58: 1806–8

17. Niu C, Clemmer KM, Bonomo RA, Rather PN: Isolation and characterization of an autoinducer synthase from *Acinetobacter baumannii*. J Bacteriol, 2008; 190: 3386–92

18. Lee HW, Koh YM, Kim J et al: Impact on empiric therapy and antibiotic resistance genes among multidrug-resistant clinical isolates of *Acinetobacter baumannii* to form biofilm and adhere to epithelial cell surfaces. Clin Microbiol Infect, 2008; 14: 49–54

19. Dong R, Guan C, Hu D et al: The correlation study on antimicrobial resistance of *Acinetobacter* related genes in clinical isolates of *Acinetobacter baumannii*. Zhonghua Wei Zhong Bing Ji Jiue Yiu Xue, 2013; 25: 493–94

20. Munoz-Price LS, Weinstein RA: *Acinetobacter* infection. N Engl J Med, 2008; 358: 1271–81

21. Masrur S, Smith EE, Saver JL et al: Dysphagia screening and hospital-acquired pneumonia in patients with acute ischemic stroke: Findings from Get with the Guidelines – Stroke. J Stroke Cerebrovasc Dis, 2013; 22: e301–9

22. Costerton JW, Stewart PS, Greenberg EP: Bacterial biofilms: A common cause of persistent infections. Science, 1999; 284: 1318–22

23. Gaidhani SV, Raskar AV, Poddar S et al: Time dependent enhanced resistance against antibiotics & metal salts by planktonic & biofilm form of *Acinetobacter haemolyticus* MMC B clinical isolate. Indian J Med Res, 2014; 140: 655–71

24. He X, Lu F, Yuan F et al: Biofilm formation caused by clinical *Acinetobacter baumannii* isolates is associated with overexpression of the AdeFGH efflux pump. Antimicrob Agents Chemother, 2015; 59: 4817–25